Welcome to our dedicated page for Brainsway SEC filings (Ticker: BRSYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Brainsway Ltd. (BRSYF) files as a foreign private issuer with the U.S. Securities and Exchange Commission, using Form 20-F for annual reporting and Form 6-K for current reports. Its 6-K filings state that they are incorporated by reference into a Form S-8 registration statement and multiple Form F-3 registration statements, showing that SEC documents are central to how the company communicates with U.S. investors.
On this page, you can review Brainsway Ltd.’s SEC filings, including Form 6-K current reports that often attach press releases as exhibits. The exhibit titles reveal key themes: neuromodulation and Deep TMS™ technologies, FDA approvals and clearances, coverage policies, and clinical trials. Examples include "BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)," "BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™," and "BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21."
Stock Titan enhances these regulatory documents with AI-powered summaries that explain the main points of lengthy filings in plain language. Real-time updates from EDGAR allow users to see new 6-K and 20-F submissions as they appear. Investors can also access and interpret other relevant forms when available, such as registration statements and any insider-related filings like Form 4, with AI-generated highlights that clarify complex disclosures.
By combining Brainsway Ltd.’s official SEC filings with AI analysis, this page helps users understand how the company reports on neuromodulation initiatives, Deep TMS developments, and related regulatory and coverage milestones.
BrainsWay Ltd., an Israel-based foreign private issuer, submitted a Form 6-K for November 2025. The report furnishes Exhibit 99.1, a press release titled “BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights.” The filing is incorporated by reference into the company’s existing Form S-8 and two Form F-3 registration statements and is signed by Chief Executive Officer Hadar Levy.
BrainsWay Ltd. furnished a Form 6-K. The filing includes an exhibit announcing a National Institutes of Health grant to a leading U.S. research team investigating accelerated Deep TMS for treatment of alcohol use disorder.
The report states this Form 6-K is incorporated by reference into the company’s Form S-8 and two Form F-3 registration statements.
BrainsWay Ltd. reported a cashless exercise of a warrant by Valor BrainsWay Holdings LLC. The warrant covered 1,500,000 American Depositary Shares at an exercise price of $9.50686 per ADS and was issued in the November 2024 private placement. At the Company’s request, the exercise was completed on a cashless basis, resulting in the issuance of 553,730 ADSs to Valor with no cash proceeds to the Company.
Brainsway Ltd. reporting persons led by Valor entities and individuals amended their Schedule 13D to disclose exercise of a warrant and updated ownership. Valor BrainsWay exercised a warrant on 10/06/2025 to purchase up to 1,500,000 ADSs at an exercise price of $9.50686 per ADS and, on a cashless basis based on the 09/30/2025 closing price, will receive 553,730 ADSs upon settlement.
The combined disclosures show the Valor group holds 5,314,950 Ordinary Shares (represented by 2,657,475 ADSs), equal to 13.7% of the class; Mr. Jonathan Shulkin and Antonio Gracias report aggregate beneficial ownership of 5,851,444 and 5,801,950 Ordinary Shares respectively, equal to 15.0% and 14.9% of the class based on 37,798,726 Ordinary Shares outstanding as of 06/30/2025. The amendment adds a joint filing agreement exhibit and states no other ADS transactions in the past 60 days aside from the warrant exercise.
The report includes condensed unaudited interim financial statements and notes for the six months ended June 30, 2025, with selected disclosures on financial instruments, investments and capital structure. The company recorded a $1,443 gain and a $69 loss on financial investments denominated in New Israeli Shekels, recognized in profit or loss per IFRS 9. It invested $5,000 in Stella Ltd. for an approximately 5% minority preferred stake measured at fair value through OCI. Share‑based payment expense totaled $552 for the six months. Subsequent strategic transactions disclosed include a $5,000 convertible loan to Neurolief with milestone tranches and an option to acquire, and a planned $2,300 equity investment for ~30% of Axis Integrated Mental Health with up to $1,000 additional milestone funding.